Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of eighty three dolars, and that is roughly 9.11 % above the existing share price of $76.07.
Cherny expects CVS Health Corp to post earnings per share (EPS) of $0.93 for the very first quarter of 2021.
The analysts price targets range from a high of hundred one dolars to a low of sixty one dolars.
From the newest earnings report of its, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net benefit of $3.25 billion. The company’s market cap is actually $99.57 billion.
Based on TipRanks.com, Merrill Lynch analyst Michael Cherny is currently ranked with four stars on a 0 5 stars ranking scale, with an average return of 11.5 % as well as a 60.53 % success rate.
CVS Health Corp. engages in the provision of health care services. It operates through the following segments: Pharmacy Services, retail or Long Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment provides pharmacy benefit management solutions. The retail or Long Term Care segment has selling of prescribed drugs and assortment of general merchandise.
The Health Care Benefits segment offers traditional, consumer-directed and voluntary health insurance products and related services, including medical, pharmacy, dental, behavioural health, medical management abilities. The Corporate segment involves in offering management and administrative services. The company was created by Stanley P. Goldstein as well as Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.